This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Case Series Study of Biliary Tract Cancer Patients in Japan

This study has been completed.
Information provided by (Responsible Party):
Kansai Hepatobiliary Oncology Group Identifier:
First received: January 3, 2011
Last updated: November 24, 2011
Last verified: November 2011
To assess the difference of prognosis between unresectable and recurrent biliary tract cancer and evaluate prognostic factors.

Biliary Tract Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Retrospective Analysis of the Difference of Prognosis Between Unresectable and Recurrent Biliary Tract Cancer

Resource links provided by NLM:

Further study details as provided by Kansai Hepatobiliary Oncology Group:

Primary Outcome Measures:
  • One year survival rate [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Overall survival time [ Time Frame: 3 years ]
  • Number of participants with adverse events [ Time Frame: 3 years ]
  • Progression free survival [ Time Frame: 3 years ]

Enrollment: 300
Study Start Date: November 2010
Study Completion Date: August 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Detailed Description:
Most patients of biliary tract cancer have advanced disease at diagnosis and often relapse despite surgery. Combination therapy of gemcitabine and cisplatin could be a standard therapy for this kind of cancer with the evidence of phase III study compared with gemcitabine alone. However the prognosis and the tolerability of chemotherapy in the patients with recurrent biliary tract cancer after radical resection might differ from those of unresectable biliary tract cancer, because the dose intensity of chemotherapy can be influenced by adjuvant chemotherapy and/or hepatic resection.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Inclusion Criteria:

  • Unresectable or recurrent biliary tract cancer

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01294085

Osaka Medical Center for Cancer and Cardiovascular Diseases
Osaka, Japan
Sponsors and Collaborators
Kansai Hepatobiliary Oncology Group
Study Director: Tatsuya Ioka, MD Osaka Medical Center for Cancer and CVD
  More Information

Responsible Party: Kansai Hepatobiliary Oncology Group Identifier: NCT01294085     History of Changes
Other Study ID Numbers: KHBO1001
UMIN000004530 ( Registry Identifier: UMIN )
Study First Received: January 3, 2011
Last Updated: November 24, 2011

Additional relevant MeSH terms:
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Biliary Tract Diseases
Digestive System Diseases processed this record on August 18, 2017